Mr LeDoux , founder, chairman and CEO of Natural Alternatives International, Inc., will focus on the development of NPA’s comments for the Food and Drug Administration's (FDA) New Dietary Ingredient (NDI) draft guidance, as well as oversight of NPA’s self-regulatory programs.
“As the leading voice of the natural products industry, NPA represents more than 1,900 members who support the health and well-being of millions of Americans,” said John Gay, NPA executive director and CEO.
“Mark’s leadership with NPA’s self-regulatory programs will benefit consumers and businesses across the country.”
LeDoux said that he was honored to be appointed as chairman of the committee.
“We need to continue to strengthen our resolve to assure the finest quality of products for the millions of people who have come to rely on our research, science and technology to provide beneficial supplements and products that are beyond reproach,” he said.
“As we work to strengthen the proper role of the federal and state agencies to help us in that objective, we must also be ever mindful that too much regulation can stifle creativity and unnecessarily increase product costs. Since safety remains our predominant concern, we also need to work with the regulatory agencies to help protect our consumers from materials masquerading as healthful products which can be criminally altered. The goal of the ComPLI committee is to assure that the delicate balance between regulation and innovation remains intact while fostering advances in health for so many in need.”